BIOSCLEAVE ░░ SHAPING OUR BIOLOGICAL NICHE ░░ DR. STANLEY SHOSTAK, EVOLUTIONARY BIOLOGIST

In this commentary on the work of Arakawa and Gins, biologist Stanley Shostak describes how Bioscleave House can be used as a setting for systematic research modeled after the guidelines of the Food and Drug Administration (FDA). If Bioscleave House were a drug, Shostak argues, it would already have passed the first phase of preclinical studies and moved well into the second phase of extending its results to a larger subject pool.

Shostak draws a distinction between biopolitics and biotopology, arguing that while biopolitics supports “anti-aging” medicine, biotopology supports “pro-aging” and living fully at every age, making it a better candidate for extending both the longevity and quality of life. Bioscleave House is one such exercise in biotopology that holds the promise of extending the plateau phase of life well into the years we currently describe as ‘old age.’

(1/1)